Buradasınız

Anasayfa » Content

Nöroprotektif tedavide yeni bir ilaç hedefi: İkinci jenerasyon tetrasiklinler

Second generation tetracyclines:A novel drug target for the neuroprotective therapy

Journal Name:

  • Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2007

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Minocycline and doxycycline are second generation tetracyclines that have high lipophilic properties and degree of access to brain. These drugs have antiinflammatory properties independent of their antimicrobial activities. Recently, it has been shown that these drugs (especially minocycline) display neuroprotective activity in animal models of global and focal cerebral ischemia, Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis, traumatic brain injury and spinal cord injury. Mainly microglial activation's inhibition, then, antiapoptotic activity and antiinflammatory activity play an important role on neuroprotection's features. To support these information by more clinical and experimental studies light the way for second generation tetracyclines, especially minocycline in cerebral diseases with neuronal death.
Bookmark/Search this post with
Abstract (Original Language): 
Minosiklin ve doksisiklin yüksek lipofilik özellikli ikinci jenerasyon tetrasiklinlerdir ve her iki ilaç da kan-beyin engelini kolayca geçebilir. Bu ilaçların antimikrobiyal özelliklerinden tamamen ayrı bir şekilde anti-inflamatuar özellliklerinin de bulunduğu belirlenmiştir. Yakın zaman önce yapılan çalışmalar minosiklinde daha belirgin olmak üzere ikinci jenerasyon tetrasiklinlerin global ve fokal beyin iskemisinde, Huntington hastalığında, amyotrofik lateral sklerozda, Parkinson hastalığında, multiple sklerozda, travmatik beyin hasarı ve medulla spinalis zedelenmesinde nöroprotektif etkileri olduğunu ortaya koymuştur. Nöroprotektif özellikte başta mikrogliyal aktivasyonun inhibisyonu olmak üzere anti-apopitotik ve anti-inflamatuar etkinliğin önemli rolü vardır. Bu bilgilerin daha fazla sayıda deneysel ve klinik çalışmalarla desteklenmesi, nöronal ölümle giden bir çok serebral hastalıkta başta minosiklin olmak üzere bu ilaçların güvenli bir şekilde kullanımına ışık tutacaktır.
FULL TEXT (PDF): 
PDF icon arastirmax-noroprotektif-tedavide-yeni-bir-ilac-hedefi-ikinci-jenerasyon-tetrasiklinler.pdf
  • 1
47-52
  • Turkish

REFERENCES

References: 

1. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline andminocycline. Clinical Pharmacokinetics 1988;15:355-66.
2. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998; 95(26):15769-74.
3. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 1999; 96(23):13496-500.
4. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model ofHuntington's disease. Nat Med 2000; 6(7):797-801.
5. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M et al. Minocycline inhibits cytochrom-c release and delays progression ofamyotrophic lateral sclerosis inmice. Nature 2002; 417(6884):74-8.
6. He Y, Appel S, Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 2001; 909(1-2):187-93.
7. Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID. Inhibition ofautoimmune encephalomyelitis by a tetracycline. Ann Neurol 2002; 51(2):215-23.
8. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 2001; 48(6):1393-9.
9. Wells EAJ, Hulbert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 2003;
126:1628-37.
10. Patel RN, Attur MG, Dave MN, Patel IV, Stuchin SA, Abramson SB et al. A novel mechanism ofaction of chemically modified tetracyclines: inhibition ofCOX-2-mediated prostaglandin E2 production. The Journal ofImmunology 1999; 163: 3459-67.
11. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN et al. A novel mechanism of action of tetracyclines: Effects onnitric oxide synthases. Proc. Natl. Acad. Sci. 1996; 93:14014-9.
12. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and
S.D.Ü. Tıp fak.
Derg
. 2007:14(1)/ 47-52
Yılmaz, Nöroprotektif tedavide ikinci jenerasyon tetrasiklinler
51
transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002;125 (6):1297-1308.
13. Clark WM, Calcagno FA, Gabler WL, Smith JR, Coull BM. Reduction ofcentral nervous system reperfusion injury in rabbits using doxycycline treatment. Stroke 1994; 25(7):1411-15.
14. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation ofmicroglia. The Journal ofNeuroscience 2001; 21(8): 2580-88.
15. Tikka TM, Koistinaho JE. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. The Journal of Immunol2001; 166(12):7527-33.
16. Tikka T, Usenius T, Tenhunen M, Keinanen R, Koistinaho J. Tetracycline derivatives and ceftriaxone, a cephalosporin antibiotic, protect neurons against apoptosis induced by ionizing radiation. J Neurochem 2001; 78(6):1409-14.
17. Zhang C, Lei B, Lam TT, Yang F, Sinha D, Tso MOM. Neuroprotection ofphotoreceptors by minocycline in light-induced retinal degeneration. Invest Opthalmol Vis Sci 2004; 45 (8): 2753-59.
18. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise ofminocycline inneurology. Lancet Neurol. 2004; 3(12):744-51.
19. Gonzalez-Scarano F, Baltuch G. Microglia as mediators ofinflammatory and degenerative diseases. Annu Rev Neurosci 1999; 22:201-40.
20. Kim SS, Kong PJ, Kim BS, Sheen DH, Nam SY, Chun W. Inhibitory action ofminocycline on lipopolysaccharide-induced release ofnitric oxide and prostaglandin E2 in BV2 microglial cells. Arch Pharm Res 2004;27(3):314-8.
21. Baptiste DC, HartwickATE, Jollimore CAB, Baldridge WH, Seigel GM, Kelly MEM. An investigation ofthe neuroprotective effects oftetracycline derivatives in experimental models ofretinal cell death. Molecular Pharmacology2004; 66 (5):1113-22.
22. Munzar P, Li H, Nicholson KL, Wiley JL, Balster RL. Enhancement ofthe discriminative stimulus effects of phencyclidine by the tetracycline antibiotics doxycycline and minocycline in rats. Psychopharmacology 2002;160:331-6.
23. Pi R, Li W, Lee NTK, Chan HHN, Pu Y, Chan LN et al. Minocycline prevents glutamate-induced apoptosis ofcerebellar granule neurons by differential regulation ofp38 and Akt pathways. Journal ofNeurochemistry 2004; 91:1219-30.
24. Dommergues MA, Plaisant F, Verney C, Gressens P. Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target forneuroprotection. Neuroscience 2003; 121:619-28.
25. Hunter CL, Quintero EM, Gilstrap L, Bhat NR,
Granholm AC. Minocycline protects basal forebrain cholinergic neurons from mu p75-saporin immunotoxic lesioning. European Journal ofNeurscience 2004; 19:3305-16.26. DuY, Ma Z, Lin S, Dodel RC, Gao F, Bales KR et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model ofParkinson's disease. Proc Natl Acad Sci USA 2001; 98(25):14669-74.
27. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C et al. Blockade ofmicroglial activation is neuroprotective inthe 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model ofParkinson disease. JNeurosci 2002; 22(5):1763-71.
28. Lin S, Zhang Y, Dodel R, Farlow MR, Paul SM, Du Y. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci Lett 2001; 315(1-
2):61-4.
29. Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM. Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol 2002; 52(1):54-61.
30. Teng YD, Choi H, Onario RC, Zhu S, Desilets FC, Lan S et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome-c release and mitigates functional deficits after spinal cord injury. PNAS 2004; 101(9): 3071-76.
31. Reasoner DK, Hindman BJ, Dexter F, Subieta A, Cutkomp J, Smith T. Doxycycline reduces early neurologic impairment after cerebral arterial air embolism in the rabbit. Anesthesiology 1997; 87:569¬76.
32. Wang C, Yang T, Noor R, Shuaib A. Delayed minocycline but not delayed mild hypothermia protects against embolic stroke. BMC Neurol 2002; 2(1):1-4.
33. Tsuji M, Wilson MA, Lange MS, Johnston MV. Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. Experimental Neurology 2004; 189:58-65.
34. Power C, Henry S, Del Bigio MR, Larsen PH, Corbett D, Imai Y et al. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. AnnNeurol 2003; 53:731-42.
35. Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH et al. Minocycline enhances MPTP toxicity to dopaminergic neurons. Journal ofNeuroscience Research 2003; 74:278-85.
36. Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci. 2004; 24(9):2182-90.
37. Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects ofminocycline with creatine in amouse model ofALS. AnnNeurol 2003; 53:267-70.
S.D.Ü. Tıp fak.
Derg
. 2007:14(1)/ 47-52
52
Yılmaz
, Nöroprotektif tedavide ikinci jenerasyon tetrasiklinler
38. Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiology ofDisease 2002; 10:268¬78.
39. Kriz J, Gowing G, Julien JP. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann Neurol 2003; 53:429-36.
40. Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J et al. Placebo-controlled phase I/II studies ofminocycline in amyotrophic lateral sclerosis. Neurology2004; 62 (10):1845-47.
41. Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PAS, et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 2003; 4:186-96.
42. Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov Disord.
2004;19(6):692-5.
43. Bonelli RM, Hödl AK, Hofmann P, Kapfhammer HP. Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int Clin Psychopharmacol 2004; 19:337-42.
44. Giuliani F, Metz LM, Wilson T, Fan Y, Bar-Or A, Yong VW. Additive effect ofthe combination ofglatiramer acetate and minocycline in a model ofMS. J Neuroimmunol. 2005; 158(1-2): 213-21.

Thank you for copying data from http://www.arastirmax.com